LOGO
LOGO

Quick Facts

Dynavax Names Eddie Gray CEO; Meeting Scheduled With FDA For HEPLISAV

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

biopharmaceutical company Dynavax Technologies Corporation (DVAX) said it appointed Eddie Gray as chief executive officer and a member of its board, effective May 1, 2013.

The company noted that Gray would replace Dino Dina, who will remain a consultant to the Company for a transition period and plans to continue serving as a member of the board.

The Company also added that Tyler Martin, President, would leave the company on May 31, 2013 and plans to remain a consultant for a transition period.

Most recently, Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc since 2008 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007.

In addition, Dynavax said it will meet with the US Food and Drug Administration in the first half of June regarding its Biologic License Application for HEPLISAV, an investigational adult hepatitis B vaccine.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19